Nanhua Biological: Revenue in the first half of 2026 increased by 384.57%-481.48% year-on-year, turning loss into profit.

South China Biology announced that from January 1 to June 30, 2026, the company expects revenue to be between 250 million and 300 million yuan, an increase of 384.57% to 481.48% year-on-year. The net profit attributable to shareholders of the listed company is expected to be between 4.2 million and 6.2 million yuan, compared to a loss of 3.4844 million yuan in the same period last year. The net profit after deducting non-recurring gains and losses is expected to be between 3.5 million and 4.5 million yuan, compared to a loss of 6.6562 million in the same period last year. The performance change is mainly due to the expansion of the lithium carbonate and renewable resources business, which increased the scale of income, and cost control measures improved cost efficiency.